Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy

Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy

Abstract Background Assessing serological inflammation is difficult in tocilizumab (TCZ)-treated rheumatoid arthritis (RA) patients, as standard inflammation parameters, like erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), are influenced by interleukin-6-receptor inhibition. Calpr...

Full description

Bibliographic Details
Main Authors: Michael Gernert, Marc Schmalzing, Hans-Peter Tony, Patrick-Pascal Strunz, Eva Christina Schwaneck, Matthias Fröhlich
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Arthritis Research & Therapy
Subjects:
Calprotectin
S100A8/S100A9
Rheumatoid arthritis
Tocilizumab
C-reactive protein
Inflammation marker
Online Access:https://doi.org/10.1186/s13075-022-02887-7

Internet

https://doi.org/10.1186/s13075-022-02887-7

Similar Items